Vaxcyte, Inc. Files 8-K Report
Ticker: PCVX · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, regulatory-filing
TL;DR
Vaxcyte filed an 8-K, mostly financial docs. Keep an eye on it.
AI Summary
On September 3, 2024, Vaxcyte, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial health and operations. No specific dollar amounts or new material events were detailed in the provided excerpt.
Why It Matters
This filing provides an official record of company events and financial information, which is crucial for investors to assess Vaxcyte's current status and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report primarily containing financial statements and exhibits, with no immediate indication of significant negative or positive events.
Key Players & Entities
- Vaxcyte, Inc. (company) — Registrant
- SutroVax, Inc. (company) — Former company name
- September 3, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing by Vaxcyte, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
When was this 8-K report filed by Vaxcyte, Inc.?
This 8-K report was filed on September 3, 2024.
What was Vaxcyte, Inc.'s former company name?
Vaxcyte, Inc.'s former company name was SutroVax, Inc.
In which state is Vaxcyte, Inc. incorporated?
Vaxcyte, Inc. is incorporated in Delaware.
What is the principal executive office address for Vaxcyte, Inc.?
The principal executive office address for Vaxcyte, Inc. is 825 Industrial Road, Suite 300, San Carlos, California, 94070.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-09-03 08:04:02
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PCVX The Nasdaq
Filing Documents
- d813919d8k.htm (8-K) — 26KB
- d813919dex991.htm (EX-99.1) — 35KB
- d813919dex992.htm (EX-99.2) — 33KB
- g813919ex99_2s10g1.jpg (GRAPHIC) — 55KB
- g813919ex99_2s11g1.jpg (GRAPHIC) — 66KB
- g813919ex99_2s12g1.jpg (GRAPHIC) — 29KB
- g813919ex99_2s13g1.jpg (GRAPHIC) — 68KB
- g813919ex99_2s14g1.jpg (GRAPHIC) — 111KB
- g813919ex99_2s15g1.jpg (GRAPHIC) — 31KB
- g813919ex99_2s16g1.jpg (GRAPHIC) — 52KB
- g813919ex99_2s17g1.jpg (GRAPHIC) — 58KB
- g813919ex99_2s18g1.jpg (GRAPHIC) — 72KB
- g813919ex99_2s19g1.jpg (GRAPHIC) — 28KB
- g813919ex99_2s1g1.jpg (GRAPHIC) — 79KB
- g813919ex99_2s20g1.jpg (GRAPHIC) — 58KB
- g813919ex99_2s21g1.jpg (GRAPHIC) — 85KB
- g813919ex99_2s22g1.jpg (GRAPHIC) — 92KB
- g813919ex99_2s23g1.jpg (GRAPHIC) — 64KB
- g813919ex99_2s24g1.jpg (GRAPHIC) — 53KB
- g813919ex99_2s25g1.jpg (GRAPHIC) — 69KB
- g813919ex99_2s26g1.jpg (GRAPHIC) — 32KB
- g813919ex99_2s27g1.jpg (GRAPHIC) — 84KB
- g813919ex99_2s28g1.jpg (GRAPHIC) — 90KB
- g813919ex99_2s29g1.jpg (GRAPHIC) — 50KB
- g813919ex99_2s2g1.jpg (GRAPHIC) — 137KB
- g813919ex99_2s30g1.jpg (GRAPHIC) — 66KB
- g813919ex99_2s31g1.jpg (GRAPHIC) — 74KB
- g813919ex99_2s32g1.jpg (GRAPHIC) — 96KB
- g813919ex99_2s33g1.jpg (GRAPHIC) — 55KB
- g813919ex99_2s34g1.jpg (GRAPHIC) — 34KB
- g813919ex99_2s3g1.jpg (GRAPHIC) — 96KB
- g813919ex99_2s4g1.jpg (GRAPHIC) — 44KB
- g813919ex99_2s5g1.jpg (GRAPHIC) — 33KB
- g813919ex99_2s6g1.jpg (GRAPHIC) — 127KB
- g813919ex99_2s7g1.jpg (GRAPHIC) — 121KB
- g813919ex99_2s8g1.jpg (GRAPHIC) — 39KB
- g813919ex99_2s9g1.jpg (GRAPHIC) — 73KB
- g813919g0903055000896.jpg (GRAPHIC) — 3KB
- 0001193125-24-211572.txt ( ) — 3440KB
- pcvx-20240903.xsd (EX-101.SCH) — 3KB
- pcvx-20240903_lab.xml (EX-101.LAB) — 18KB
- pcvx-20240903_pre.xml (EX-101.PRE) — 11KB
- d813919d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VAXCYTE, INC. Date: September 3, 2024 By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer